Balchem Corp. 10-Q Summary: Period Ended September 30, 2002
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation, filed for the period ended September 30, 2002. The company develops, manufactures, and markets specialty performance ingredients for food, feed, and medical sterilization industries. Operations are divided into three segments: Specialty Products, Encapsulated/Nutritional Products, and Unencapsulated Feed Supplements.
Key Financial Metrics
Revenue and Profit (Nine Months Ended Sept 30, 2002):
- Net Sales: $45,842,000 (up 43.0% from $32,062,000 in 2001).
- Gross Profit: $17,856,000 (Gross Margin: 39.0%).
- Operating Earnings: $9,494,000 (up from $5,445,000 in 2001).
- Net Earnings: $5,797,000 (up from $3,569,000 in 2001).
- Diluted EPS: $1.17 (up from $0.74 in 2001).
Liquidity and Balance Sheet (As of Sept 30, 2002):
- Cash and Cash Equivalents: $3,395,000.
- Working Capital: $10,651,000 (Current Assets $17,425,000 less Current Liabilities $6,774,000).
- Total Debt: $11,758,000 (Current portion $1,745,000; Long-term $10,013,000).
- Stockholders' Equity: $31,804,000.
Cash Flow (Nine Months Ended Sept 30, 2002):
- Operating Cash Flow: $8,634,000 (significant increase from $1,439,000 in 2001).
- Investing Cash Flow: $(7,218,000), driven primarily by capital expenditures of $7,337,000.
- Financing Cash Flow: $(1,141,000), due to debt principal payments and dividends.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Encapsulated/Nutritional Products segment, which saw sales increase 76.3% to $21,781,000. This growth was attributed to new products, new applications, and the inclusion of human choline products from the 2001 acquisition.
- Segment Performance: Specialty Products sales grew 2.5%. The Unencapsulated Feed Supplements segment sales increased to $7,774,000 (compared to partial year 2001 data) but incurred an operating loss of $257,000 due to lower margin feed products.
- Operating Expenses: Increased 16.2% to $8,362,000, largely due to increased advertising and personnel costs to support sales and R&D in the encapsulated segment. However, expenses as a percentage of sales decreased from 22.4% to 18.2%.
- Capital Expenditures: Significantly higher at $7,337,000 compared to $1,194,000 in the prior year, reflecting facility expansions in Verona, Missouri, and a new office lease in New Hampton, NY.
Outlook, Risks, and Management Commentary
- Capital Projects: The company is expanding manufacturing and distribution facilities in Verona, MO, to handle encapsulated choline products. Total capital expenditures for 2002 are projected at approximately $10,000,000.
- Debt and Covenants: The company maintains a $13,500,000 term loan (outstanding balance $11,758,000) and a $3,000,000 revolving credit facility (undrawn). Management confirmed compliance with all restrictive covenants as of September 30, 2002.
- Stock Repurchase: The board authorized an extension of the stock repurchase program for up to an additional 600,000 shares through June 30, 2003.
- Contingencies: The 2001 acquisition agreement includes potential contingent consideration of up to $2,750,000 based on future sales performance; none has been earned or paid as of this date.
- Risks: Market risk is primarily exposure to interest rate fluctuations on the variable-rate term loan. A 100 basis point increase would increase annual interest expense by approximately $118,000. The company has no material exposure to foreign currency or commodity price risks.
Investor Verification Checklist
- Verify the sustainability of the 76.3% sales growth in the Encapsulated/Nutritional Products segment.
- Monitor the operating loss in the Unencapsulated Feed Supplements segment and its impact on overall margins.
- Confirm the completion and ROI of the $7.3M capital expenditures in the Verona, MO facility.
- Review the status of the $3,000,000 revolving credit facility renewal due May 31, 2003.
- Track the execution of the extended stock repurchase program and its impact on share count.